Add. info to newsletter ”2cureX GmbH receives contribution for the development of IndiTreat® tests in immuno-oncology”
2cureX AB published on 2018-10-03 a corporate news that the company’s German subsidiary 2cureX GmbH (”2cureX”) had received a grant of from the German Federal Ministry of Education and Research (BMBF). The grant was approved in March 2017. The total amount of the grant for 2cureX and its collaborator University Medical Center Hamburg-Eppendorf was 1,188,000 EUR. The payment is subject to approved on-site inspection at the company’s facilities and that 2cureX co-finance the project with EUR 378,000. The on-site inspection was successfully conducted on 2018-09-27. The net profit to be obtained by 2cureX is EUR 567,000.
2cureX has received a grant of EUR 1,188,000 from the German Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung, BMBF) to adapt the IndiTreat® to individualized immuno-oncology treatment. The project is run in collaboration with the University Medical Center Hamburg-Eppendorf (Universitätsklinikum Hamburg-Eppendorf, UKE). 2cureX is co-financing the project with
EUR 378,000. The project will run until February 2020. The grant was approved in March 2017 subject to a successfully approved on-site inspection at the company’s facilities. The on-site inspection was successfully conducted on 2018-09-27. The EUR 810,000 payments (of which 2cureX receives EUR 567,000) are provided on a quarterly basis until the end of the project in February 2020.
Sedermera Fondkommission is the Certified Adviser of 2cureX.
For more information about 2cureX:
Ole Thastrup, CEO;
Phone: +45 22 11 53 99;
2cureX has developed a test called IndiTreat® (Individual Treatment Design), which is a patented method for selecting the right drug for the right patient. IndiTreat® establishes thousands of 3D micro-tumors that are functionally similar to the patient’s tumor. From a large panel of approved cancer treatments IndiTreat® selects the best treatment for the individual patient. IndiTreat® is expected to become a standard tool in the treatment design for cancer patients.
IndiTreat® is currently being clinically validated in colorectal and ovarian cancer.
The company is listed at the Nasdaq First North stock exchange in Stockholm (symbol “2CUREX”).